eligibility_summary
Inclusion: Adults 18–75 with CNLC IIIa HCC plus PVTT/HVTT/IVCTT, R0 resection, recovered with rising post-op AFP, GPC3+ IHC, ECOG 0–1, Child‑Pugh ≤7, adequate labs, venous access, >12‑wk survival. Contraception required. Exclusion: residual/metastatic disease pre-apheresis, >2 yrs post‑op, pregnant/lactinating, active viral infection, uncontrolled illness (effusions/encephalopathy), recent therapy/steroids/vaccines, prior cell therapy, anticoagulation, other malignancy, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib, single-arm, open-label trial evaluating CT011 in resected hepatocellular carcinoma at high risk of recurrence. Intervention: CT011, an autologous chimeric antigen receptor T-cell (CAR‑T) therapy targeting glypican‑3 (GPC3). Mechanism: patient T cells are engineered to express a CAR that binds GPC3 on tumor cells, antigen engagement triggers CAR signaling, T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity to eliminate GPC3+ cells. Targets: GPC3-expressing HCC cells, engages immune effector pathways via activated CAR-T cells. Primary aims: safety, efficacy, and cellular kinetics.